Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Trial Profile

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 22 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top